Genetic protection modifications: Moving beyond the binary distinction between therapy and enhancement for human genome editing

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Genetic protection modifications : Moving beyond the binary distinction between therapy and enhancement for human genome editing. / Mikkelsen, Rasmus Christen B; Frederiksen, Henriette Reventlow S.; Gjerris, Mickey; Holst, Bjørn; Hyttel, Poul; Luo, Yonglun; Freude, Kristine; Sandoe, Peter.

I: CRISPR Journal, Bind 2, Nr. 6, 2019, s. 362-369.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Mikkelsen, RCB, Frederiksen, HRS, Gjerris, M, Holst, B, Hyttel, P, Luo, Y, Freude, K & Sandoe, P 2019, 'Genetic protection modifications: Moving beyond the binary distinction between therapy and enhancement for human genome editing', CRISPR Journal, bind 2, nr. 6, s. 362-369. https://doi.org/10.1089/crispr.2019.0024

APA

Mikkelsen, R. C. B., Frederiksen, H. R. S., Gjerris, M., Holst, B., Hyttel, P., Luo, Y., ... Sandoe, P. (2019). Genetic protection modifications: Moving beyond the binary distinction between therapy and enhancement for human genome editing. CRISPR Journal, 2(6), 362-369. https://doi.org/10.1089/crispr.2019.0024

Vancouver

Mikkelsen RCB, Frederiksen HRS, Gjerris M, Holst B, Hyttel P, Luo Y o.a. Genetic protection modifications: Moving beyond the binary distinction between therapy and enhancement for human genome editing. CRISPR Journal. 2019;2(6):362-369. https://doi.org/10.1089/crispr.2019.0024

Author

Mikkelsen, Rasmus Christen B ; Frederiksen, Henriette Reventlow S. ; Gjerris, Mickey ; Holst, Bjørn ; Hyttel, Poul ; Luo, Yonglun ; Freude, Kristine ; Sandoe, Peter. / Genetic protection modifications : Moving beyond the binary distinction between therapy and enhancement for human genome editing. I: CRISPR Journal. 2019 ; Bind 2, Nr. 6. s. 362-369.

Bibtex

@article{fa06d698083941b4beebbc3f28a666a6,
title = "Genetic protection modifications: Moving beyond the binary distinction between therapy and enhancement for human genome editing",
abstract = "The current debate and policy surrounding the use of genome editing in humans typically relies on a binary distinction between therapy and human enhancement. Here, we argue that this dichotomy fails to take into account perhaps the most significant potential uses of CRISPR-Cas9 genome editing in humans. We argue that genetic treatment of sporadic Alzheimer's disease, breast and ovarian cancer predisposing BRCA1/2 mutations, and the introduction of human immunodeficiency virus resistance in humans should be considered within a new category of genetic protection treatments. We suggest that if this category is not introduced, life-altering research might be unnecessarily limited by current or future policy. Otherwise ad hoc decisions might be made, which introduce a risk of unforeseen moral costs, and might overlook or fail to address some important opportunities.",
author = "Mikkelsen, {Rasmus Christen B} and Frederiksen, {Henriette Reventlow S.} and Mickey Gjerris and Bj{\o}rn Holst and Poul Hyttel and Yonglun Luo and Kristine Freude and Peter Sandoe",
year = "2019",
doi = "10.1089/crispr.2019.0024",
language = "English",
volume = "2",
pages = "362--369",
journal = "CRISPR Journal",
issn = "2573-1599",
publisher = "Mary AnnLiebert, Inc. Publishers",
number = "6",

}

RIS

TY - JOUR

T1 - Genetic protection modifications

T2 - Moving beyond the binary distinction between therapy and enhancement for human genome editing

AU - Mikkelsen, Rasmus Christen B

AU - Frederiksen, Henriette Reventlow S.

AU - Gjerris, Mickey

AU - Holst, Bjørn

AU - Hyttel, Poul

AU - Luo, Yonglun

AU - Freude, Kristine

AU - Sandoe, Peter

PY - 2019

Y1 - 2019

N2 - The current debate and policy surrounding the use of genome editing in humans typically relies on a binary distinction between therapy and human enhancement. Here, we argue that this dichotomy fails to take into account perhaps the most significant potential uses of CRISPR-Cas9 genome editing in humans. We argue that genetic treatment of sporadic Alzheimer's disease, breast and ovarian cancer predisposing BRCA1/2 mutations, and the introduction of human immunodeficiency virus resistance in humans should be considered within a new category of genetic protection treatments. We suggest that if this category is not introduced, life-altering research might be unnecessarily limited by current or future policy. Otherwise ad hoc decisions might be made, which introduce a risk of unforeseen moral costs, and might overlook or fail to address some important opportunities.

AB - The current debate and policy surrounding the use of genome editing in humans typically relies on a binary distinction between therapy and human enhancement. Here, we argue that this dichotomy fails to take into account perhaps the most significant potential uses of CRISPR-Cas9 genome editing in humans. We argue that genetic treatment of sporadic Alzheimer's disease, breast and ovarian cancer predisposing BRCA1/2 mutations, and the introduction of human immunodeficiency virus resistance in humans should be considered within a new category of genetic protection treatments. We suggest that if this category is not introduced, life-altering research might be unnecessarily limited by current or future policy. Otherwise ad hoc decisions might be made, which introduce a risk of unforeseen moral costs, and might overlook or fail to address some important opportunities.

U2 - 10.1089/crispr.2019.0024

DO - 10.1089/crispr.2019.0024

M3 - Journal article

C2 - 31860350

VL - 2

SP - 362

EP - 369

JO - CRISPR Journal

JF - CRISPR Journal

SN - 2573-1599

IS - 6

ER -

ID: 233589263